Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Jun;28 Suppl 1(Suppl 1):e26472.
doi: 10.1002/jia2.26472.

Limited awareness and use of HIV post-exposure prophylaxis among people vulnerable to HIV acquisition in Western Kenya: a cross-sectional analysis

Affiliations
Observational Study

Limited awareness and use of HIV post-exposure prophylaxis among people vulnerable to HIV acquisition in Western Kenya: a cross-sectional analysis

Glenna Schluck et al. J Int AIDS Soc. 2025 Jun.

Abstract

Introduction: HIV post-exposure prophylaxis (PEP) can prevent HIV acquisition and facilitates linkage to pre-exposure prophylaxis (PrEP) for people with ongoing vulnerability. We assessed PEP awareness and use in Western Kenya.

Methods: We used cross-sectional screening/enrolment data from the Multinational Observational Cohort of HIV and other Infections (MOCHI) study. Eligible participants had behavioural vulnerability to HIV and were ages 14-55 years. Participants completed questionnaires on demographics, sexual/behavioural history, and PEP/PrEP awareness and use. Depression was assessed using the Patient Health Questionnaire (PHQ-9) with none/minimal, mild and moderate/severe depression defined as PHQ-9 scores of 0-4, 5-9 and ≥10, respectively. We used multivariable robust Poisson regression with purposeful variable selection to estimate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs) for factors associated with PEP awareness.

Results: From December 2021 to May 2023, 398 participants indicated whether they heard of PEP. The median age was 22 years (IQR 19-24), 316/399 (79.2%) were female and 315/389 (81.0%) reported sex work or transactional sex. One hundred fourteen (28.6%) participants had never heard of PEP, of whom 79 (69.3%) had also not heard of PrEP. Among 284 participants who had heard of PEP, 74 (26.1%) did not know where to access it. Seventy-one participants (17.8%) had taken PEP, of whom 17 (23.9%) encountered problems accessing PEP such as unavailability (n = 5) or prohibitive expense (n = 4). In the final model, only <12 years of education (aPR 1.65 [95% CI 1.16-2.34]) and not cohabitating (aPR 2.81 [95% CI = 1.11-7.08]) were associated with never having heard of PEP. Among participants who had heard of PEP, factors associated with not knowing where to access PEP were <12 years of education (aPR 2.20 [95% CI 1.37-3.54]) and depression (mild aPR 1.86 [95% CI 1.17-2.96]; moderate/severe aPR 1.84 [95% CI 1.09-3.09], compared to none/minimal).

Conclusions: Despite enrolling a behaviourally vulnerable group potentially eligible for PEP, we identified substantial gaps in PEP awareness, access and use. Demand generation and improved access to PEP are needed to maximize the impact on reducing HIV incidence. Interventions to improve PEP awareness and access may be most impactful for people with lower education or when coupled with mental health services.

Keywords: HIV; health risk behaviours; implementation science; post‐exposure prophylaxis; pre‐exposure prophylaxis; sexually transmitted infection.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Number and percentage of participants who, at enrolment, are potentially eligible for PEP, heard of PEP, knew where to access PEP and ever used PEP. All percentages are out of the total number of participants who are potentially eligible for PEP (n = 398).

Similar articles

Cited by

References

    1. Public health service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. Can Dis Wkly Rep. 1990;16 Suppl 2:4–13. - PubMed
    1. 1998 guidelines for treatment of sexually transmitted diseases. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47(Rr‐1):1–111. - PubMed
    1. World Health Organization & International Labour Organization . Post‐exposure prophylaxis to prevent HIV infection: Joint WHO/ILO guidelines on post exposure prophylaxis (PEP) to prevent HIV infection; 2007. Available from: https://apps.who.int/iris/handle/10665/43838. Accessed 4 January 2023.
    1. Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, Struble KA, et al. Antiretroviral postexposure prophylaxis after sexual, injection‐drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2005;54(Rr‐2):1–20. - PubMed
    1. Announcement: updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection‐drug use, or other nonoccupational exposure to HIV—United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(17):458. - PubMed

Publication types

LinkOut - more resources